CD79A and trigeminal neuralgia: These structural aberrations may precipitate the onset and progression of trigeminal neuralgia by fostering the release of host-derived antimicrobial peptides (AMPs) or secretory immunoglobulin A (IgA), thus perpetuating a cascade of inflammatory events culminating in neuronal dysfunction and pain.